Literature DB >> 12627493

Use of a rodent model to show that varicella-zoster virus ORF61 is dispensable for establishment of latency.

Hitoshi Sato1, Lesley Pesnicak, Jeffrey I Cohen.   

Abstract

Varicella-zoster virus (VZV) results in a latent infection in humans after primary infection. Latency has also been established in guinea pigs and rats after inoculation with the virus. It was found that infection of cotton rats with the Oka vaccine strain of VZV results in a latent infection. To begin to identify which genes are required for latency, we infected cotton rats with VZV strain Oka that is deleted for ORF61. ORF61 protein transactivates certain VZV promoters and enhances the infectivity of viral DNA in transient transfections. Deletion of ORF61 results in abnormal syncytia and impairs the growth of VZV in vitro. Inoculation of cotton rats with ORF61-deleted Oka virus resulted in latent VZV infection in the nervous system similar to that seen for animals infected with parental virus. Thus, the cotton rat can be used to study the ability of mutants in the Oka vaccine strain of VZV to establish latent infection. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627493     DOI: 10.1002/jmv.10326

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  19 in total

1.  Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells.

Authors:  Jenna Christensen; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Postentry events are responsible for restriction of productive varicella-zoster virus infection in Chinese hamster ovary cells.

Authors:  Renée L Finnen; Kara R Mizokami; Bruce W Banfield; Guang-Yun Cai; Scott A Simpson; Lewis I Pizer; Myron J Levin
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 3.  Review: The neurobiology of varicella zoster virus infection.

Authors:  D Gilden; R Mahalingam; M A Nagel; S Pugazhenthi; R J Cohrs
Journal:  Neuropathol Appl Neurobiol       Date:  2011-08       Impact factor: 8.090

4.  Simian varicella virus gene expression during acute and latent infection of rhesus macaques.

Authors:  Christine Meyer; Amelia Kerns; Alex Barron; Craig Kreklywich; Daniel N Streblow; Ilhem Messaoudi
Journal:  J Neurovirol       Date:  2011-11-04       Impact factor: 2.643

5.  A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture.

Authors:  Aruna P N Ambagala; Tammy Krogmann; Jing Qin; Lesley Pesnicak; Jeffrey I Cohen
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

6.  Simian varicella virus pathogenesis.

Authors:  Ravi Mahalingam; Ilhem Messaoudi; Don Gilden
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

7.  Varicella-zoster virus ORF47 protein kinase, which is required for replication in human T cells, and ORF66 protein kinase, which is expressed during latency, are dispensable for establishment of latency.

Authors:  Hitoshi Sato; Lesley Pesnicak; Jeffrey I Cohen
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Jesse Dewane; Joshua Walker; Wayne Gray; Ilhem Messaoudi
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  The varicella-zoster virus open reading frame 63 latency-associated protein is critical for establishment of latency.

Authors:  Jeffrey I Cohen; Edward Cox; Lesley Pesnicak; Shamala Srinivas; Tammy Krogmann
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.